Roche to give up Tamiflu data; India fast-tracking price controls; Covis buys 5 Sanofi drugs;

@FiercePharma: India's top court rebuffs Merck, lets generic Januvia roll despite patent, at least for now. More | Follow @FiercePharma

@EricPFierce: FDA has no comment on judge's ruling to make Teva's Plan B available OTC to adolescents. Story | Follow @EricPFierce

> Roche ($RHHBY) is giving up its fight and will release its data on Tamiflu to researchers who have raised questions about its effectiveness. Story

> Switzerland-based specialty pharmaceutical company Covis Pharma has acquired the U.S. rights to 5 Sanofi ($SNY) drugs for an undisclosed amount. Release

> India may give drugmakers only 45 days to comply with new pricing for about 350 drugs it is putting under price controls, including batches already in the supply chain. News

> Biotest is recalling a lot of BIVIGAM Immune Globulin Intravenous (Human),10% Liquid after visible particles were found in some vials during an inspection. Statement

> Drug shortages continue to add to the concerns of cancer patients. Story

> Following Virgina's lead, the Florida legislature is on a path toward approving a law that would put restrictions on the use of biosimilars. Story

Medical Device News

@FierceMedDev: St. Jude faces fresh crop of Riata suits. Story | Follow @FierceMedDev

@MarkHFierce: David vs Goliath (J&J). David won. And then he lost on appeal. More | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics is finally going public--at about 14% of its preliminary IPO pricing. News | Follow @DamianFierce

> J&J recalls Animas infusion pumps over hypoglycemia risk. Item

> J&J victory: Appeals court tosses $482M stent patent defeat. Story

> Swiss pick up baton for breath Dx research. More

Biotech News

@FierceBiotech: In case you missed it yesterday: Fierce's 10 top biotech billionaires. Special report | Follow @FierceBiotech

@JohnCFierce: Receptos--experienced team with CEO Faheem Hasnain (Facet)--files for IPO. S-1 | Follow @JohnCFierce.

@RyanMFierce: Looks like BMY and VRTX have struck another let's-see-what-happens deal in Hep C. Phase II only pact for now. Release | Follow @RyanMFierce

> Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data. Article

> AstraZeneca reports hit-and-miss PhIII for arthritis pill. Report

> Astellas, Ambrx seal $300M cancer ADC deal. News

And Finally... Despite the public hue and cry on-going FDA inspections at compounding pharacies indicate many still didn't clean up their act. Story

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.